Provided by Tiger Trade Technology Pte. Ltd.

Viridian Therapeutics, Inc.

29.25
+0.08000.27%
Post-market: 28.90-0.3500-1.20%19:32 EST
Volume:1.94M
Turnover:56.80M
Market Cap:2.79B
PE:-9.68
High:30.17
Open:30.14
Low:28.94
Close:29.17
52wk High:34.29
52wk Low:9.90
Shares:95.44M
Float Shares:80.72M
Volume Ratio:1.11
T/O Rate:2.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0205
EPS(LYR):-3.0722
ROE:-49.89%
ROA:-30.08%
PB:8.89
PE(LYR):-9.52

Loading ...

Viridian Therapeutics Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
Feb 03

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Demant (OtherWILLF), Viridian Therapeutics (VRDN) and Tenet Healthcare (THC)

TIPRANKS
·
Feb 03

Exploring High Growth Tech Stocks In The US Market

Simply Wall St.
·
Jan 26

Did FDA Priority Review and EU Push for Thyroid Eye Drug Just Shift Viridian Therapeutics' (VRDN) Investment Narrative?

Simply Wall St.
·
Jan 18

Viridian Therapeutics Grants Stock Options to New Employee as Inducement

Reuters
·
Jan 09

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jan 09

Viridian Therapeutics Inc : UBS Initiates Coverage With Buy Rating and Target Price $50

THOMSON REUTERS
·
Jan 07

Viridian Therapeutics Inc - Veligrotug Bla Accepted for Ted With Pdufa Date June 30, 2026

THOMSON REUTERS
·
Jan 06

Viridian Therapeutics Inc - Ind Submitted for Vrdn-008; Hv Data Expected in 2H 2026

THOMSON REUTERS
·
Jan 06

Viridian Therapeutics : Expects Its Current Business Plans to Be Funded Through Profitability

THOMSON REUTERS
·
Jan 06

FDA Accepts Viridian Therapeutics' Veligrotug BLA for Priority Review

Reuters
·
Jan 06

Viridian Therapeutics Chief Legal Officer Jennifer Tousignant Reports Disposal of Common Shares

Reuters
·
Jan 03

Exploring US High Growth Tech Stocks In December 2025

Simply Wall St.
·
Dec 25, 2025

Viridian Therapeutics Inc : Needham Raises Target Price to $42 From $34

THOMSON REUTERS
·
Dec 23, 2025

FDA Grants Priority Review to Viridian Therapeutics' Veligrotug for Thyroid Eye Disease

Reuters
·
Dec 22, 2025

Viridian Therapeutics Inc - Pdufa Target Action Date Set for June 30, 2026

THOMSON REUTERS
·
Dec 22, 2025

Viridian Therapeutics Announces Bla Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease

THOMSON REUTERS
·
Dec 22, 2025

Viridian Therapeutics Inc - Plans to Submit Marketing Authorization Application to Ema in Q1 2026

THOMSON REUTERS
·
Dec 22, 2025

FDA Review Of Veli For Thyroid Eye Disease Might Change The Case For Investing In Viridian Therapeutics (VRDN)

Simply Wall St.
·
Dec 21, 2025

Viridian Therapeutics Inc : Wedbush Raises Target Price to $47 From $42

THOMSON REUTERS
·
Dec 10, 2025